in a hybridization reaction. To enable spatial transcriptomics and proteomics from one FFPE slide, NanoString introduced the GeoMx® Digital Spatial Profiler in 2019. The GeoMx DSP combines whole tissue imaging with gene expression and protein data for single cell resolution in a spatial context. NanoString's product pipeline includes the development of the CosMx™ Spatial Molecular Imager, a single-cell imaging platform that is FFPE-compatible and powered by spatial multiomics. It allows researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. In addition, NanoString has developed the AtoMx™ Spatial Informatics Platform, a cloud-based informatics solution with advanced analytics and global collaboration capabilities, which is expected to launch in 2022. The AtoMx platform provides a comprehensive, integrated ecosystem for spatial biology insights, enabling global data sharing and collaboration. Overall, NanoString's continued investment in innovation has led to the development of a range of advanced research tools that offer high sensitivity, precision, and spatial resolution, allowing researchers to gain deep insights into biological systems. References Biotechnology companies of the United States Companies based in Seattle Companies established in 2003 Medical tests Cancer screening 2013 initial public offerings